Literature DB >> 15999149

Genomics of pancreatic cancer: does it make any improvement in diagnosis, prognosis and therapy?

László Kopper1, Attila Zalatnai, József Tímár.   

Abstract

Pancreatic cancer (PanC) is an extremely lifethreatening neoplasm due to its late discovery, rapid progression and resistance to chemo- and radiotherapy. In the past years a significant research attention turned to this cancer. Extensive genomic analysis of PanC revealed numerous alterations, however, none of them emerged yet as a key regulator of tumor progression. Our increasing knowledge on the molecular targets in various cancer types started to change their management. Examples of success of the molecular therapies (in CML, GIST, NSCLC) may initiate more activity in pancreatic cancer as well.

Entities:  

Mesh:

Year:  2005        PMID: 15999149     DOI: 10.1007/BF02893369

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  38 in total

1.  Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival.

Authors:  Kenichi Kuwahara; Tamito Sasaki; Yukio Kuwada; Masateru Murakami; Souichirou Yamasaki; Kazuaki Chayama
Journal:  Pancreas       Date:  2003-05       Impact factor: 3.327

Review 2.  The challenge of pathway and environment-mediated drug resistance.

Authors:  E A Sausville
Journal:  Cancer Metastasis Rev       Date:  2001       Impact factor: 9.264

3.  Relationship between expressions of E-cadherin and alpha-catenin and biological behaviors of human pancreatic cancer.

Authors:  Yu-Jun Li; Yun-Xiao Meng; Xiang-Rui Ji
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2003-08

4.  Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase.

Authors:  Galit Elad-Sfadia; Roni Haklai; Eyal Ballan; Hans-Joachim Gabius; Yoel Kloog
Journal:  J Biol Chem       Date:  2002-07-30       Impact factor: 5.157

5.  Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer.

Authors:  Johanna Louhimo; Henrik Alfthan; Ulf-Håkan Stenman; Caj Haglund
Journal:  Oncology       Date:  2004       Impact factor: 2.935

6.  Expression of MUC5AC and MUC6 in invasive ductal carcinoma of the pancreas and relationship with prognosis.

Authors:  Ma Jinfeng; Wataru Kimura; Ichiro Hirai; Fumiaki Sakurai; Toshiyuki Moriya; Masaomi Mizutani
Journal:  Int J Gastrointest Cancer       Date:  2003

7.  Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma.

Authors:  Hirofumi Uehara; Masaki Miyamoto; Kentaro Kato; Yuma Ebihara; Hiroyuki Kaneko; Hiroyuki Hashimoto; Yoshihiro Murakami; Ryunosuke Hase; Ryo Takahashi; Seiji Mega; Toshiaki Shichinohe; You Kawarada; Tomoo Itoh; Shunichi Okushiba; Satoshi Kondo; Hiroyuki Katoh
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

Review 8.  Implications of growth factor alterations in the treatment of pancreatic cancer.

Authors:  Márk Juhász; Barbara Nitsche; Peter Malfertheiner; Matthias P A Ebert
Journal:  Mol Cancer       Date:  2003-01-07       Impact factor: 27.401

Review 9.  Molecular regulation of pancreatic stellate cell function.

Authors:  Robert Jaster
Journal:  Mol Cancer       Date:  2004-10-06       Impact factor: 27.401

10.  ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma.

Authors:  R Grützmann; J Lüttges; B Sipos; O Ammerpohl; F Dobrowolski; I Alldinger; S Kersting; D Ockert; R Koch; H Kalthoff; H K Schackert; H D Saeger; G Klöppel; C Pilarsky
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.